Twist Bioscience (TWST) Competitors

Twist Bioscience (NASDAQ:TWST) and Verona Pharma (NASDAQ:VRNA) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment.

Does the MarketBeat Community believe in TWST or VRNA?

Verona Pharma received 231 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 81.10% of users gave Verona Pharma an outperform vote while only 59.34% of users gave Twist Bioscience an outperform vote.

Company	Underperform	Outperform
Twist Bioscience	Outperform Votes 108 59.34%	Underperform Votes 74 40.66%
Verona Pharma	Outperform Votes 339 81.10%	Underperform Votes 79 18.90%

Does the media prefer TWST or VRNA?

In the previous week, Verona Pharma had 7 more articles in the media than Twist Bioscience. MarketBeat recorded 12 mentions for Verona Pharma and 5 mentions for Twist Bioscience. Verona Pharma's average media sentiment score of 1.26 beat Twist Bioscience's score of 0.97 indicating that Verona Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verona Pharma	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend TWST or VRNA?

Twist Bioscience presently has a consensus target price of $50.40, suggesting a potential upside of 43.39%. Verona Pharma has a consensus target price of $87.44, suggesting a potential downside of 2.89%. Given Twist Bioscience's higher probable upside, analysts plainly believe Twist Bioscience is more favorable than Verona Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Verona Pharma	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10

Which has better valuation & earnings, TWST or VRNA?

Verona Pharma has lower revenue, but higher earnings than Twist Bioscience. Verona Pharma is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$347.68M	6.06	-$208.73M	-$3.25	-10.82
Verona Pharma	$118.54M	61.60	-$54.37M	-$2.00	-45.03

Which has more risk and volatility, TWST or VRNA?

Twist Bioscience has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of TWST or VRNA?

85.9% of Verona Pharma shares are held by institutional investors. 3.0% of Twist Bioscience shares are held by insiders. Comparatively, 4.8% of Verona Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is TWST or VRNA more profitable?

Verona Pharma has a net margin of 0.00% compared to Twist Bioscience's net margin of -59.76%. Twist Bioscience's return on equity of -32.69% beat Verona Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-59.76%	-32.69%	-25.25%
Verona Pharma	N/A	-79.54%	-43.49%

Summary

Verona Pharma beats Twist Bioscience on 13 of the 19 factors compared between the two stocks.